Abstract: The present invention relates, in general, to methods of treating diseases resulting from interactions between immune complexes and Fc receptors. In particular, the present invention relates to methods of modulating the clearance of antibody-coated cells from the circulation by inhibiting phagocytosis and to methods of modulating the interaction of immune complexes with tissue Fc receptors. Further, the invention relates to methods of modulating the activation of immunological processes mediated by Fc receptor activation resulting from antibody-antigen/receptor interaction.
Abstract: The present invention provides antibodies (e.g., monoclonal antibodies) that specifically binds to mammalian IgE (e.g., dog IgE). In some embodiments the antibodies bind to an epitope between amino acids 145–166 of mammalian IgE; in other embodiments the antibodies bind to an epitope between amino acids 356–374 of mammalian IgE. The antibodies may be used for allergen reactivity testing in human subjects or animal subjects for veterinary purposes.
Abstract: This invention also provides a method of generating antigen specific human suppressor CD8+CD28? T cells. This invention further provides a method of generating allopeptide antigen specific human suppressor CD8+CD28? T cells. Methods of tent for reduction of risk of rejection of allografts and xenografts and autoimmune diseases using the human suppressor CD8+CD28? T cells so produced are also provided, as are methods of preventing rejection and autoimmune diseases, and vaccines comprising the produced suppressor T cells. Methods of diagnosis to determine whether a level of immuno-suppressant therapy requires a reduction are provided.
Type:
Grant
Filed:
June 15, 2000
Date of Patent:
December 5, 2006
Assignee:
The Trustees of Columbia University in the City of New York
Abstract: In one aspect of the present invention there is provided a method for determining the risk of developing a complication of preterm birth in a patient born before 40 weeks of gestation or weighing 10% less than the average for the patient's gestational age. The method involves measuring serum IGF-I and/or IGF-I binding protein levels after birth of the patient to obtain an IGF-I or IGF-I binding protein level; and correlating said IGF-I or IGF-I binding protein level with an in utero baseline level of IGF-I or IGF-I binding protein based on gestational age matched mean levels in utero, wherein an IGF-I or IGF-I binding protein level below the mean gestational age in utero level indicates the patient is at an increased risk of developing a complication of preterm birth. The complications of preterm birth include retinopathy of prematurity, developmental delay, mental retardation, bronchopulmonary dysplasia, and intraventricular hemorrhage.
Abstract: The present invention relates to novel complexes of major histocompability complex (MHC) molecules and uses of such complexes. In one aspect, the invention relates to loaded MHC complexes that include at least one MHC molecule with a peptide-binding groove and a presenting peptide non-covalently linked to the MHC protein. In another aspect, the invention features single chain MHC class II peptide fusion complexes with a presenting peptide covalently linked to the peptide binding grove of the complex. MHC complexes of the invention are useful for a variety of applications including: 1) in vitro screens for identification and isolation of peptides that modulate activity of selected T cells, including peptides that are T cell receptor antagonists and partial agonists, and 2) methods for suppressing or inducing an immune response in a mammal.
Type:
Grant
Filed:
May 3, 2001
Date of Patent:
November 28, 2006
Assignee:
Altor Bioscience Corporation
Inventors:
Peter R. Rhode, Jin-An Jiao, Martin Burkhardt, Hing C. Wong
Abstract: A method of inducing tolerance to a transplant transplanted from a donor to a subject is disclosed. The method comprises (a) restricting outflow of a fluid from a portion of the circulatory system of the subject; and (b) administering a dose of bone marrow cells derived from the donor to a body part delimiting said portion of the circulatory system, prior to, concomitantly with or following transplantation of the transplant, thereby inducing tolerance to the transplant in the subject.
Abstract: The present invention is related to antibodies directed to the antigen PDGFD and uses of such antibodies. In particular, in accordance with the present invention, there are provided fully human monoclonal antibodies directed to the antigen PDGFD. Nucelotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDR's), specifically from FR1 through FR4 or CDR1 through CDR3, are provided. Hybridomas or other cell lines expressing such immunoglobulin molecules and monoclonal antibodies are also provided.
Type:
Grant
Filed:
January 7, 2002
Date of Patent:
November 14, 2006
Assignee:
Amgen Fremont, Inc.
Inventors:
Jose R. F. Corvalan, Xiao-Chi Jia, Xiao Feng, Xiao-dong Yang, Francine Chen, Gadi Gazit, Richard Weber, Binyam Bezabeh
Abstract: The invention relates to compositions which bind T cell inhibitory receptor molecules and modulate T cell activity, and methods of using such compositions. Such compositions include biliary glycoprotein binding agents. Methods for modulating killer T cell activities, including cytotoxicity and proliferation also are provided.
Abstract: A new method to capture, purify and expand antigen-specific T lymphocytes has been developed using magnetic beads coated with recombinant MHC class I molecules. This method was optimized using homogenous populations of naive T cells purified from mice transgenic for the 2C T cell receptor (TCR). These T cells were captured on beads coated with MHC class I molecules and the relevant antigenic peptides. MHC and peptide specificity was confirmed by the usage of irrelevant MHC peptide combinations. An enrichment of 800 to 1600 fold was measured, using 2C T cells mixed with irrelevant T cells, starting from a 2C T cell frequency of 1/3000. The same approach was used to purify antigen-specific CD8+ T cells from total CD8+ T cells from naive mice. The recovered cells could be expanded and specifically kill target cells in vitro; they had a significant effect in vivo as well. We expect this procedure to be suitable to purify and expand in vitro tumor- and virus-specific killer T cells for use in cell therapy.
Type:
Grant
Filed:
February 23, 2004
Date of Patent:
October 24, 2006
Assignee:
Ortho-McNeil Pharmaceutical, Inc.
Inventors:
Alain T. Luxembourg, Michael R. Jackson, Per A. Peterson
Abstract: The method for immune serum globulin purification relates to the purification of immune globulins from blood plasma with a high degree of efficiency and a high rate of recovery. The immune globulin source is Cohn's fraction I+II+III or II+III prepared from plasma or plasma intermediates by precipitation of the paste at pH 6.7 to 6.8 in the presence of 20% ethanol and 80% purified water. A glycine extraction is followed by an anion exchange chromatography column step to achieve a significantly high yield and high purity of the concentrated protein.
Type:
Grant
Filed:
May 13, 2005
Date of Patent:
October 24, 2006
Assignee:
Hemacare Corporation
Inventors:
Joshua Levy, Fred Rothstein, Bahman Shimiaei
Abstract: Provided are methods and compositions for the photodynamic therapy (PDT) of ocular conditions characterized by the presence of unwanted choroidal neovasculature, for example, neovascular age-related macular degeneration. The selectivity and sensitivity of the PDT method can be enhanced by combining the PDT with an anti-angiogenesis factor, for example, angiostatin or endostatin, or with an apoptosis-modulating factor. Furthermore, the selectivity and sensitivity of the PDT may be further enhanced by coupling a targeting moiety to the photosensitizer so as to target the photosensitizer to choroidal neovasculature.
Type:
Grant
Filed:
February 9, 2001
Date of Patent:
October 24, 2006
Assignee:
Massachusetts Eye and Ear Infirmary
Inventors:
Joan W. Miller, Evangelos S. Gragoudas, Reem Z. Renno
Abstract: The present invention relates to a new member of the serine protease family, Ztryp3. Members of this family play a role in carefully controlled processes, such as blood coagulation, fibrinolysis, complement activation, fertilization, and hormone production. These enzymes are also used in a variety of diagnostic, therapeutic, and industrial contexts.
Abstract: A method of enriching mesenchymal precursor sells including the step of enriching for cells based on at least two markers. The markers may be either i) the presence of markers specific for mesenchymal precursor cells, ii) the absence of markers specific for differentiated mesenchymal cells, or iii) expression levels of markers specific for mesenchymal precursor cells. The method may include a first solid phase sorting step utilizing MACS recognizing expression of the antigen to the STRO-1 Mab, followed by a second sorting step utilizing two color FACS to screen for the presence of high level STRO-1 antigen expression as well as the expression of VCAM-1.
Type:
Grant
Filed:
July 7, 2000
Date of Patent:
October 17, 2006
Assignee:
Angioblast Systems, Incorporated
Inventors:
Paul Simmons, Andrew Zannettino, Stan Gronthos
Abstract: The present invention concerns polypeptides comprising a variant Fc region. More particularly, the present invention concerns Fc region-containing polypeptides that have altered effector function as a consequence of one or more amino acid modifications in the Fc region thereof.
Abstract: Methods for increasing yields of regulatory T cells, useful, e.g., in transplantation contexts. Use of antigen presenting cells and anti-CD28 are also described.
Type:
Grant
Filed:
October 14, 2003
Date of Patent:
October 17, 2006
Assignee:
Schering Corporation
Inventors:
Franck J. Barrat, Pieter Andre Boonstra, Huub Savelkoul, Rene de Waal Malefyt, Anne O'Garra
Abstract: The present invention features a novel human protein (ANK), nucleotide sequences encoding human ANK, and assays for ANK activity, including assays to identify therapeutics and diagnostic assays, e.g., for susceptibility to diseases such as arthritis. In related aspects the invention features expression vectors and host cells comprising polynucleotides that encode a human ANK. The present invention also relates to antibodies that bind specifically to a human ANK, and methods for producing human ANK polypeptides.
Type:
Grant
Filed:
January 5, 2001
Date of Patent:
October 17, 2006
Assignee:
The Board of Trustees of the Leland Stanford Junior University
Inventors:
David Mark Kingsley, Michelle Deanetta Johnson, Andrew Manlap Ho
Abstract: A novel polypeptide ligand, p30, or LIGHT, for herpes virus entry mediator, HVEM, is provided. LIGHT is useful for modulating immune responses and in inhibiting infection and/or subsequent proliferation by herpesvirus. HVEM fusion proteins are also provided. Methods for treating subjects with lymphoid cell disorders, tumors, autoimmune diseases, inflammatory disorders or those having or suspected of having a herpesvirus infection, utilizing p30 and the fusion proteins of the invention, are also provided.
Type:
Grant
Filed:
September 28, 2001
Date of Patent:
October 10, 2006
Assignee:
La Jolla Institute for Allergy and Immunology
Abstract: The present invention provides methods, improved cell culture medium and kits for promoting hematopoietic and mesenchymal stem and lineage-specific cell proliferation and differentiation by growth in the presence of angiotensinogen, angiotensin I (Al), AI analogues, AI fragments and analogues thereof, angiotensin II (AII), AII analogues, AII fragments or analogues thereof or AII AT2 type 2 receptor agonists, either alone or in combination with other growth factors and cytokines.
Abstract: A simple and highly efficient method for cloning cDNAs including CD27 (SEQ ID NO:28) from mammalian expression libraries based on transient expression in mammalian host cells has been discovered. Novel expression vectors allowing highly efficient construction of mammalian cDNA libraries are disclosed. The cloning method of the invention which has been used to clone genes for cell surface antigens of human lymphocytes, has general application in gene cloning. Cell surface antigens cloned according to the present invention have been purified, and the nucleotide and amino acid sequences determined. These antigens have diagnostic and therapeutic utility in immune-mediated infections in mammals, including humans.
Type:
Grant
Filed:
April 17, 2001
Date of Patent:
October 10, 2006
Assignee:
The General Hospital Corporation
Inventors:
Brian Seed, Alejandro Aruffo, David Camerini